Australia's largest stock trading and investment forum Australia's #1 stock forum

1AD adalta limited

0.00%

0.2¢

Ann: Positive AD-214 Phase I extension study results, page-204

First 204 Last

Share
Profile

Follow
debono

23,258 Posts.

828

27/03/24

16:24

Post #: 73087148
Share

Originally posted by rlj ↑

Depends on the partnering route taken as to what the funds from the upfront are used for. The way I understand it:

Option A = Out license to big pharma = sale of the AD214 asset with an upfront payment & contingent milestones = no further spend on AD214 for Adalta, can use the upfront to develop the pipeline of other drugs

Option B = JV Partner with Private equity = AD214 into SPV, JV partner pays Adalta for a portion of equity in SPV = in phase II either the costs are shared with the JV partner or the JV partner pays 100% (depending on the deal and how much equity is given away) with hope of selling for more (to big pharma) at some point

Expand

I could be totally wrong however I think the way it was worded is that they might look for a bite of a couple of apples. Hopefully not too long to find out. Market price normally leads news so we wait...dum de dum...

1AD Price at posting: 2.5¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

'Not possible' to port renewable gas: ACCC takes AGN to court

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

First 204 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.2¢		Change 0.000(0.00%)		Mkt cap ! $2.142M

Open	High	Low	Value	Volume
0.2¢	0.2¢	0.2¢	$6.816K	3.407M

Buyers (Bids)

No.	Vol.	Price($)
22	20338807	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	9024228	16

View Market Depth

No.	Vol.	Price($)
22	20338807	0.002
14	39953497	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	9024228	16
0.004	13062108	11
0.005	3071002	8
0.006	1963830	1
0.007	133335	1

Last trade - 16.10pm 27/06/2025 (20 minute delay)

1AD (ASX) Chart

Ann: Positive AD-214 Phase I extension study results, page-204

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Boss extends June win streak with boosted Alta Mesa extraction rates

'Not possible' to port renewable gas: ACCC takes AGN to court

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Positive AD-214 Phase I extension study results, page-204

Top Stories

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Boss extends June win streak with boosted Alta Mesa extraction rates

'Not possible' to port renewable gas: ACCC takes AGN to court

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News